

Appendix Table. Epidemiologic data of CTX-M-15-producing *Escherichia coli* isolates from 7 countries\*

EC PhG	Location	Origin	Date	PFGE type	Isolate no.	MLST	Antimicrobial drug resistance pattern†	<i>bla</i> <sub>CTX-M-15</sub> ‡	Plasmid features		RFLP type#
									Size, kb§	rep content¶	
B2 <sub>3</sub>	Portugal, Spain	Urine	2002–2003	C15–1	2	ST354	<b>Ac, Gm, Km, Na, (Ni), Sm, Su, Tb, Tp</b>	P (85)	<b>85</b>	<b>FII (85)</b>	A
B2 <sub>3</sub>	Portugal	Wound	2003	C15–2	1	ST405	<b>Ac, Gm, Km, Na, Ni, Sm, Su, Tb, Tp</b>	P (85)	<b>85</b>	<b>FII (85)</b>	A
B2 <sub>3</sub>	Paris, France, Portugal	Catheter (n = 1), urine (n = 1)	2001–2004	C15–3	2	ST131	Ac, Cp, <b>Gm, Km, Na, Sm, Su, Tc, Tb, Tp</b>	P (85)	<b>85</b>	<b>FII (85)</b>	A
–	India	–	2000	C15–4	1	–	<b>Ac, Gm, Km, Sm, Tb, Tc</b>	P (85)	<b>85</b>	<b>FII (85)</b>	A
–	India	–	2000	C15–5	1	–	<b>Ac, Gm, Km, Sm, Tb, Tc</b>	P (85)	<b>85</b>	<b>FII (85)</b>	A
–	India	–	2000	C15–6	1	–	<b>Ac, Gm, Km, Sm, Tb, Tc</b>	P (85)	<b>85</b>	<b>FII (85)</b>	A
–	India	–	2000	C15–7	1	–	<b>Ac, Gm, Km, Sm, Tb, Tc</b>	P (120)	<b>120</b>	<b>FII + FIA (120)</b>	B
B2 <sub>3</sub>	Kuwait	Urine	2004	C15–3a	1	ST131	Ac, Cp, Na, Te	P (120)	120	<b>FII + FIA (120)</b>	B
B2 <sub>3</sub>	Switzerland	Urine	2004	C15–3b	1	ST131	Ac, Cp, Gm, Km, Na, Tc, Tb	C	120	<b>FII + FIA (120)</b>	B
B2 <sub>3</sub>	Canada, Spain	Urine (n = 2)	2000–2002	C15–3c	2	ST131	Ac, Cp, Gm, Km, Na, Tc, Tb	P (120)	120	<b>FII + FIA (120)</b>	B
B2 <sub>3</sub>	Portugal, Canada, Paris, France	Urine (n = 2)	2001–2004	C15–3d	3	ST131	Ac, (Cp), <b>(Gm), (Km), Na, (Sm), (Tc), (Tb)</b>	P (120), n = 1; C, n = 2	120	<b>FII + FIA (120)</b>	B
B2 <sub>3</sub>	Paris and Reims, France	Urine (n = 3), feces (n = 1)	2003–2005	C15–3e	4	ST131	Ac, (Cp), <b>(Gm), (Km), Na, (Sm), (Tc), (Tb)</b>	C	120	<b>FII + FIA (120)</b>	ND
B2 <sub>3</sub>	Reims, France	Urine	2005	C15–3f	1	ST131	Ac, Cp, Na	P (150)	<b>150</b>	<b>FII + FIA + FIB (150)</b>	FE
B2 <sub>3</sub>	Kuwait	Urine	2004	C15–3g	1	ST131	Ac, Cp, Gm, Km, Na, Sm, Tc, Tb, Su, Tp	P (100)	100 + 150	<b>FII + FIB (100)</b>	ND
B2 <sub>3</sub>	Switzerland	Urine	2004	C15–3h	1	ST131	Ac, Cp, Gm, Km, Na, Su, Tc, Tb, Tp	P (160)	160	<b>FII + FIA (160)</b>	N
B2 <sub>3</sub>	Paris, France	Urine	2000	C15–8	1	ST695	Ac, Na, Sm, Su, <b>Tc, Tp</b>	P (85)	<b>85</b>	<b>FII + FIB (85)</b>	C1
B2 <sub>3</sub>	Switzerland	Wound	2004	C15–9	1	ST28	Ac	P (85)	<b>85 + 120</b>	<b>FII (85)</b>	C1
D <sub>1</sub>	Switzerland	Respiratory tract	2004	C15–10	1	<i>fumC</i> 13	Ac, Gm, Km, Tc, Tb,	P (110)	110	<b>FII + FIB (110)</b>	E
D <sub>1</sub>	Paris, France	Urine	2000	C15–11	1	<i>fumC</i> 26	Ac, Ak, Cp, Cm, Gm, Km, Na, Sm, Su, <b>Tc, Tb, Tp</b>	P (100)	<b>100</b>	<b>FII (100)</b>	ND
D <sub>1</sub>	Spain	Wound	2002	C15–12	1	ST405	Ac, Cm, Gm, Km, Na, Sm, Su, Tc, <b>Tb, Tp</b>	P (100)	<b>100 + 120</b>	<b>FII + FIA (100)</b>	J
D <sub>1</sub>	Canada	Urine	2000	C15–13	1	<i>fumC</i> 132	Ac, Cm, Cp, Gm, Km, Na, Sm, Su, Tb, Tp	P (85)	85 + 120	<b>FII (85)</b>	C2
D <sub>1</sub>	Kuwait	Wound	2004	C15–14	1	<i>fumC</i> 4	Ac, Cp, Na, Sm, Su, Tc, Tp	C	120 + 100	<b>FII + FIA + FIB (120)</b>	ND
D <sub>1</sub>	Switzerland	Urine	2004	C15–15	2	ST405	Ac, Cp, Gm, Km, Na, Sm, Su, Tc, Tb, Tp	C	85 + 120	<b>FII + FIA + FIB (85)</b>	ND

D <sub>1</sub>	Kuwait	Respiratory tract	2004	C15–16	1	ST405	Ac, Cp, Gm, Km, Na, Sm, Su, Tc, Tb, Tp	P (150)	150	<b>FII + FIA + FIB</b> (150)	O
D <sub>1</sub>	Kuwait	Urine	2004	C15–17	1	ST405	Ac, Ak, Cp, Gm, Km, Na, Sm, Su, Tc, Tb, Tp	P (160), C	160	<b>FII + FIA + FIB</b> (160)	ND
D <sub>1</sub>	Switzerland	Urine	2004	C15–18	1	<i>fumC</i> 26	Ac, Cp, Gm, Km, Na, Su, Tc, Tb, Tp	C	<b>120</b>	<b>FII + FIA + FIB</b> (120)	L
D <sub>1</sub>	Paris, France	Urine	2001	C15–19	1	<i>fumC</i> 88	Cm, Cp, Gm, Na, Su, Tc, Tb, Tp	P (85)	<b>85</b>	<b>FII</b> (85)	C
–	India	–	2000	C15–20	1	–	<b>Ac, Cm, Sm</b>	P (85)	<b>85</b>	<b>FII</b> (85)	G
–	India	–	2000	C15–21	1	–	<b>Ac, Gm, Km, Sm, Tc, Tb</b>	P (85)	<b>85</b>	<b>FII</b> (85)	H
A <sub>1</sub>	Kuwait	Blood	2004	C15–22	1	–	Ac, Gm, Km, Sm, Tc, Tb	–	–	<b>FII</b>	FE
A <sub>1</sub>	Paris, France	Urine	2001	C15–23	1	–	Ac, Ak, Cm, Cp, Gm, Km, Na, Ni, Sm, Su, Tc, Tb, Tp	C	100	<b>FII + FIA + FIB</b> (100)	F
A <sub>1</sub>	Canada	Urine	2001	C15–24	1	–	Ac, Cp, Gm, Km, Na, Sm, Su, Tc, Tb	P (110)	110	<b>FII + FIA + FIB</b> (110)	K
A <sub>1</sub>	Kuwait	Respiratory tract (n = 1), urine (n = 1)	2004	C15–25	2	–	Ac, (Ak), Cp, Gm, Km, Na, (Ni), (Sm), Su, Tc, Tb, Tp	P (120)	120	<b>FII + FIA</b> (120)	N
A <sub>1</sub>	Reims, France	Urine	2005	C15–26	2	–	Ac, Cm, Cp, Gm, Km, Na, Su, Tb, Tp	P (120)	<b>120 + 100</b>	<b>FII + FIA + FIB</b> (120)	ND
A <sub>1</sub>	Kuwait	Urine	2004	C15–27	1	–	Ac, Cp, Km, Na, Sm, Su, Tc, Tb, Tp	P (85)	85 + 100	<b>FII + FIB</b> (85)	D
B <sub>1</sub>	Paris, France	Urine	2003	C15–28	1	–	Ac, Km, Tc, Tb	P (85)	85	<b>FII</b> (85)	M
B <sub>1</sub>	Paris, France	Urine	2003	C15–29	1	–	Ac, Km, Sm, Su, <b>Tc, Tb</b> , Tp	P (80)	<b>80</b>	<b>FII</b> (85)	P
B <sub>1</sub>	Paris, France	Urine	2002	C15–30	1	–	Ac, Cm, Cp, Gm, Km, Na, Ni, Sm, Su, Tc, Tb, Tp	P (100), C	100 + 40	<b>FII + FIA</b> (100)	I

\*EC PhG, *E. coli* phylogenetic group; PFGE, pulsed-field gel electrophoresis; MLST, multilocus sequence typing; RFLP, restriction fragment length polymorphism; ST, sequence type.

†Transferability of antimicrobial drug resistance to a given drug is indicated in **boldface**. Drugs in parentheses are not associated with resistance in all isolates. Ac, amoxicillin-clavulanic acid; Gm, gentamicin; Km, kanamycin; Na, nalidixic acid; Ni, nitrofurantoin; Sm, streptomycin; Su, sulfonamide; Tb, tobramycin; Tp, trimethoprim; Tc, tetracycline; Cp, ciprofloxacin; Ak, amikacin; Cm, chloramphenicol.

‡Chromosomal (C) or plasmid (P) location of the *bla*<sub>CTX-M-15</sub> gene was determined by hybridization of probes with *I-CeuI*-digested genomic DNA. Size of the plasmid in kb is indicated in parentheses.

§Plasmid size and content were determined by hybridization of S1 nuclease-digested genomic DNA on transconjugants (or wild type if transfer failed). Successful plasmid transfer by conjugation or transformation is indicated in **boldface**.

¶Replicon content of plasmids with *bla*<sub>CTX-M-15</sub> genes was determined by PCR, hybridization, and sequencing of replicons. Replicons hybridizing in the same band as that of the *bla*<sub>CTX-M-15</sub> gene are indicated in **boldface**. Numbers in parentheses represent plasmid sizes in kb.

#ND, not done; FE, failed extraction.